Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

Assessment of oral toxicokinetics based on the phys-chem of 2,6 DTBPindicates that the substance is lipophilic and can diffuse across the lipid domain of cellular membranes.

The absorption in the GI tract is expected to occur predominantly via simple diffusion. The mean predicted fractional absorption of 2,6 DTBP in the human is 0.89 (Simcyp v.10.0). Significant first pass effects are not expected for 2,6 DTBP. From the results of the 28-day repeat dose toxicity study in rats there is evidence of systemic exposure to 2,6 DTBP following oral gavage dosing: histopathological examination of the tissues at the end of the study identified changes in the liver in animals dosed at 600 mg/kg body weight/day.Additional evidence of systemic exposure was noted in a preliminary reproduction screening toxicity test study in rats exposed to 2,6 DTBP by oral gavage dosing for between 4 and 6 weeks: animals dosed at 750 mg/kg body weight/day showed severe reactions to treatment with sedation, ataxia, recumbancy, tremors and spasms. Following systemic exposure to 2,6 DTBP in the circulation, a rapid metabolism via glucuronisation and sulphatation may be predicted from the chemical structure with excretion mainly via the kidney. The information for a chemically similar compound would imply a short half life for 2,6 DTBP at the very low level of potential human exposure with no likelihood for bioaccumulation.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential
Absorption rate - oral (%):
89
Absorption rate - dermal (%):
89

Additional information